Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial (2020)

Peer-Reviewed Study · de Groot S, Lugtenberg RT, Cohen D, Welters MJP, Ehsan I, Vreeswijk MPG, et al.; Dutch Breast Cancer Research Group (BOOG) · June 23, 2020

de Groot S et al., 2020-06-23: DIRECT, a multicentre randomised phase 2 trial in 131 patients: a three-day fasting-mimicking diet around neoadjuvant chemotherapy produced no difference in toxicity, more radiological responses, and a higher rate of near-complete pathological response in per-protocol analysis.

there was no difference in toxicity between both groups, despite the fact that dexamethasone was omitted in the FMD group. A radiologically complete or partial response occurs more often in patients using the FMD (OR 3.168, P = 0.039).

Abstract

de Groot S et al., 2020-06-23: DIRECT, a multicentre randomised phase 2 trial in 131 patients: a three-day fasting-mimicking diet around neoadjuvant chemotherapy produced no difference in toxicity, more radiological responses, and a higher rate of near-complete pathological response in per-protocol analysis. Funded by Pink Ribbon (2012.WO31.C155) and Amgen (20139098). Conflicts: V.D.L. holds equity in L-Nutra, which sells fasting-mimicking diet products; H.P. holds shares in a company that invested in L-Nutra – the maker interest the book's claim turns on. Dexamethasone was omitted in the FMD arm, so the comparison is not purely dietary. Trial NCT02126449. Study type: randomized trial.